Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-23-066126
Filing Date
2023-03-09
Accepted
2023-03-09 16:17:51
Documents
3
Group Members
ABINGWORTH BIOVENTURES 8 LPABINGWORTH BIOVENTURES VII LPABINGWORTH LLPCARLYLE GENESIS UK LLCCARLYLE HOLDINGS I GP INC.CARLYLE HOLDINGS I GP SUB L.L.C.CARLYLE HOLDINGS I L.P.CARLYLE INVESTMENT MANAGEMENT L.L.C.CG SUBSIDIARY HOLDINGS L.L.C.TC GROUP, L.L.C.

Document Format Files

Seq Description Document Type Size
1 SC 13G d822401dsc13g.htm SC 13G 195462
2 EX-24 d822401dex24.htm EX-24 11540
3 EX-99 d822401dex99.htm EX-99 13984
  Complete submission text file 0001193125-23-066126.txt   223137
Mailing Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Business Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004 202 729 5626
Carlyle Group Inc. (Filed by) CIK: 0001527166 (see all company filings)

EIN.: 452832612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G
SIC: 6282 Investment Advice

Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Subject) CIK: 0001783183 (see all company filings)

EIN.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91182 | Film No.: 23719980
SIC: 2834 Pharmaceutical Preparations